What oral medications are used for acute gout flares and long‑term urate‑lowering therapy?

Oral Medications for Gout

For acute gout flares, use corticosteroids (prednisolone 30-35 mg/day for 3-5 days), NSAIDs, or low-dose colchicine (1 mg loading dose followed by 0.5 mg one hour later); for long-term management, start allopurinol at 100 mg/day and titrate upward every 2-4 weeks to achieve serum urate <6 mg/dL. 1, 2

Acute Gout Flare Treatment

First-Line Options (Choose Based on Contraindications)

Corticosteroids are the preferred first-line choice when no contraindications exist, as they are safer, equally effective as NSAIDs, and low-cost 2. Use prednisolone 30-35 mg/day (or equivalent) for 3-5 days 1.

NSAIDs are equally effective alternatives. Any NSAID works—there is no evidence that indomethacin is superior to naproxen or ibuprofen 2. Add a proton pump inhibitor if gastrointestinal risk exists 1.

Colchicine must be started within 12 hours of flare onset for optimal efficacy 1. Use 1 mg loading dose followed by 0.5 mg one hour later on day 1 1, 2. This low-dose regimen is as effective as high-dose (4.8 mg) but with significantly fewer gastrointestinal side effects 1.

Critical Contraindications to Avoid

• Colchicine: Avoid in severe renal impairment (GFR <30 mL/min) and never combine with strong P-glycoprotein/CYP3A4 inhibitors (cyclosporin, clarithromycin, ketoconazole, ritonavir) due to risk of severe toxicity 1
• NSAIDs: Avoid in renal disease, heart failure, or cirrhosis 2
• Corticosteroids: Contraindicated in systemic fungal infections 2

When to Escalate

For severe flares involving multiple joints, consider combination therapy (colchicine + NSAID or colchicine + corticosteroid) 1. For patients with frequent flares and contraindications to all standard options, IL-1 blockers should be considered 1.

Long-Term Urate-Lowering Therapy (ULT)

When to Initiate ULT

Start ULT in these situations 1, 3:

• Recurrent flares (≥2 per year)
• Tophi present
• Radiographic joint damage
• Urate kidney stones
• Young age at onset (<40 years)
• Very high serum urate (>8 mg/dL or 480 µmol/L)
• Comorbidities: chronic kidney disease, hypertension, ischemic heart disease, heart failure

Do not start ULT after a first gout attack or with infrequent attacks 2. The American College of Physicians strongly recommends against initiating long-term ULT in most patients after a first attack.

First-Line ULT: Allopurinol

Allopurinol is the first-line agent for all patients, including those with moderate-to-severe chronic kidney disease 1, 3.

Dosing algorithm 1, 3:

1. Start at 100 mg/day (lower if CKD present—adjust to creatinine clearance)
2. Increase by 100 mg increments every 2-4 weeks
3. Titrate until serum urate <6 mg/dL (360 µmol/L)
4. For severe gout (tophi, chronic arthropathy, frequent attacks), target <5 mg/dL (300 µmol/L) until crystal dissolution occurs 1
5. Never maintain serum urate <3 mg/dL long-term 1

Second-Line Options

If allopurinol fails to reach target at maximum appropriate dose or is not tolerated 1:

• Switch to febuxostat (start <40 mg/day) 3
• Switch to a uricosuric (probenecid, benzbromarone)
• Combine allopurinol with a uricosuric

Important caveat: Febuxostat carries an FDA black box warning for increased cardiovascular death and heart failure hospitalization risk—avoid in patients with cardiovascular disease 4, 5.

Mandatory Flare Prophylaxis During ULT Initiation

When starting any ULT, provide prophylaxis for at least 3-6 months 1, 3. This is a strong recommendation with high-quality evidence 6.

Prophylaxis options 1:

• Colchicine 0.5-1 mg/day (reduce dose in renal impairment; avoid with statins due to neurotoxicity/myotoxicity risk)
• Low-dose NSAIDs if colchicine contraindicated or not tolerated

Treat-to-Target Strategy

Monitor serum urate regularly and maintain <6 mg/dL lifelong 1, 3. This treat-to-target approach is strongly recommended by EULAR and ACR guidelines, though the American College of Physicians notes this strategy is supported by observational rather than experimental evidence 6.

Key Clinical Pitfalls

1. Starting allopurinol at high doses: Always start low (100 mg/day or less) to minimize flare risk during initiation 1, 3
2. Failing to provide prophylaxis: Initiating ULT without anti-inflammatory prophylaxis leads to increased flare frequency and treatment abandonment 1
3. Not titrating to target: Simply prescribing allopurinol 300 mg without monitoring serum urate fails in most patients—80-90% can reach target with proper dose titration 7
4. Using colchicine with drug interactions: Co-prescription with cyclosporin or clarithromycin can cause fatal toxicity 1
5. Stopping ULT prematurely: Serum urate <6 mg/dL must be maintained lifelong to prevent crystal reformation 1